Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...